Genetic Testing Market Analysis

Genetic Testing Market Analysis

To get key market trends

  Download Free Sample

Based on the products & services, the market is classified into kits & reagents, and software & services. The kits & reagents segment dominated the market with revenue of USD 12.1 billion in 2023.
 

• Next generation sequencing (NGS) kits provide a high-throughput method for sequencing entire genomes or specific regions. These kits include reagents for library preparation, sequencing, and data analysis, enabling comprehensive genetic analysis for both research and clinical diagnostics. For example, Illumina’s TruSight Oncology 500 kit allows for comprehensive profiling of cancer-related genes. It includes reagents for library preparation and sequencing, enabling clinicians to identify mutations and tailor cancer treatments to individual patients.
   
• The presence of several companies offering various types of kits and reagents reflects the growing adoption of genetic testing across multiple applications, thereby driving segmental growth.
   

Based on the test type, the genetic testing market is classified into predictive testing, carrier testing, prenatal & newborn testing, diagnostic testing, pharmacogenomics testing, nutrigenomics, and other test types. The prenatal and newborn testing segment dominated the market with market share of 39.6% in 2023.
 

• The dominance of prenatal and newborn screening is driven by the development of advanced testing kits and products, such as non-invasive prenatal testing (NIPT) or cell-free fetal DNA testing.
   
• Additionally, many developed countries have mandated newborn screening programs that test for a panel of genetic and metabolic disorders shortly after birth. For example, according to the Centers for Disease Control and Prevention (CDC), millions of babies in the U.S. are routinely screened each year using a few drops of blood from the newborn’s heel to detect certain genetic, endocrine, and metabolic disorders.
   
• Increasing awareness about genetic disorders such as Down syndrome, Edwards syndrome, and Patau syndrome is a major factor driving the adoption of prenatal screening, thereby contributing to market growth.
   

Based on application, the genetic testing market is classified into cancer treatment, tissue typing for transplantation, forensic identity testing, ancestry testing, paternity testing, and other applications. The cancer treatment segment is expected to reach USD 23.8 billion by 2032.
 

• Advances in genetic testing technologies have improved the ability to detect genetic predispositions to cancer at earlier stages. Early detection can lead to earlier intervention and potentially better patient outcomes.
   
• Additionally, genetic testing data contributes to the development of new cancer treatments and therapies through clinical trials. This fosters innovation in cancer treatment strategies and expands the range of options available to patients, thereby driving market growth.
   

Based on techniques, the genetic testing market is classified into polymerase chain reaction, DNA sequencing, cytogenetic testing, microarrays, and gene expression profiling. The DNA sequencing segment dominated the market with market share of 41.6% in 2023.
 

• The reduction in the cost of sequencing per base pair has made DNA sequencing more accessible and affordable, leading to increased adoption among healthcare providers and researchers.
   
• Advancements in next generation sequencing (NGS) technologies are driving this growth. These technologies have significantly reduced the costs and time required for DNA sequencing. Platforms from companies like Illumina and Thermo Fisher Scientific have transformed the field, enabling high-throughput sequencing at a fraction of previous costs.
   
• Additionally, the wide range of applications for DNA sequencing techniques is expected to further drive the segment's growth.
   

Based on end-use, the genetic testing market is classified into hospitals & clinics, diagnostic laboratories, forensic laboratories, and other end-users. The hospitals & clinics segment is expected to exhibit 12.2% CAGR between 2024 and 2032.
 

• Hospitals and clinics are increasingly adopting genetic testing to personalize treatment plans based on patients' genetic profiles. This trend is driven by a growing understanding of how genetic variations influence disease susceptibility and drug response.
   
• Furthermore, collaborations between genetic testing companies and healthcare providers are facilitating the integration of testing services into existing hospital and clinic workflows, making testing more accessible and contributing to the segment's growth. 
   

In 2023, North America secured a substantial market share of 46.3% in the genetic testing market and is expected to dominate throughout the forecast period.
 

• The region boasts a strong presence of major market players and leading research institutions focused on genetic research, fostering a conducive environment for the growth of the market.
   
• North America also benefits from a well-established healthcare infrastructure and a high level of awareness regarding genetic disorders, which drives the demand for genetic testing services and products such as kits, reagents, and software.
   
• Additionally, the U.S. government has been investing in research and development through various initiatives and grants. For instance, in November 2021, DNAScript received a grant of USD 2.2 million from the National Human Genome Research Institute to support its research.
   
• These investments not only drive innovation but also foster a competitive environment that encourages companies to push the boundaries of genetic testing technology. Overall, these initiatives by the U.S. government have significantly contributed to the growth of the market in the region.
   

Germany to experience the considerable growth rate in the Europe market.
 

• European countries have established comprehensive regulatory frameworks for genetic testing, ensuring quality control and patient safety. The European Union’s In Vitro Diagnostic Regulation (IVDR), which came into full effect in May 2022, provides clearer guidelines and increased transparency, thereby boosting market growth by ensuring the reliability and safety of genetic tests and driving the demand for genetic testing services.
   
• Additionally, Europe has seen significant investments in Next-Generation Sequencing technologies, which enable more efficient and cost-effective genetic testing. This technological advancement has made it feasible to offer a broader range of genetic tests to a larger population.
   

The Asia Pacific genetic testing market is expected to grow with a significant CAGR of 13.3% during the forecast period.
 

• The region is witnessing a notable increase in research and development activities, particularly in biotechnology, pharmaceuticals, and genetic engineering. This surge is fuelled by a growing emphasis on precision medicine, personalized healthcare, and advancements in genetic testing.
   
• Moreover, the rising prevalence of genetic diseases such as cystic fibrosis, sickle cell anemia, and Huntington's disease in the region is driving the need for genetic testing and personalized medicine. This trend is leading to increased demand for custom genetic testing services, further fuelling market growth.
   
• Furthermore, rapid industrialization and urbanization are leading to increased investments in healthcare infrastructure and research facilities, coupled with supportive government initiatives and funding for genomics research and development. For instance, the Chinese government has made substantial investments in genomics research, including support for genetic testing.